{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:11:07Z","timestamp":1792001467951,"version":"4.4.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.eururo.2025.09.4137","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T04:44:53Z","timestamp":1759553093000},"page":"151-162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cost-effectiveness Analysis of Treatments for Bacillus Calmette-Gu\u00e9rin\u2013unresponsive Carcinoma in Situ of the Bladder"],"prefix":"10.1016","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5219-2978","authenticated-orcid":false,"given":"Amanda A.","family":"Myers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruchika","family":"Talwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Hensley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yair","family":"Lotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy N.","family":"Luckenbaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wassim","family":"Kassouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vignesh T.","family":"Packiam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary D.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.Alfred","family":"Witjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdana","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Porten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah M.","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly K.","family":"Bree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iakovos","family":"Toumazis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3546-9928","authenticated-orcid":false,"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2025.09.4137_b0005","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/S0140-6736(17)30874-7","article-title":"Evolution and patterns of global health financing 1995\u20132014: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries","volume":"389","author":"Dieleman","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2025.09.4137_b0010","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.3050","article-title":"Management, surveillance patterns, and costs associated with low-grade papillary stage Ta non-muscle-invasive bladder cancer among older adults, 2004\u20132013","volume":"5","author":"Bree","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.eururo.2025.09.4137_b0015","series-title":"BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment guidance for industry","author":"US Food and Drug Administration","year":"2018"},{"key":"10.1016\/j.eururo.2025.09.4137_b0020","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.09.4137_b0025","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3233\/BLC-159002","article-title":"Clarification of bladder cancer disease states following treatment of patients with intravesical BCG","volume":"1","author":"Lerner","year":"2015","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.eururo.2025.09.4137_b0030","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.09.4137_b0035","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.09.4137_b0040","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200167","article-title":"IL-15 superagonist NAI in BCG-unresponsive non-muscle-invasive bladder cancer","volume":"2","author":"Chamie","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.eururo.2025.09.4137_b0045","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/bju.16509","article-title":"Long-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancer","volume":"135","author":"Taylor","year":"2025","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.09.4137_b0050","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.eururo.2024.12.002","article-title":"The financial burden of localized and metastatic bladder cancer","volume":"87","author":"Scilipoti","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.09.4137_b0055","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.eururo.2024.08.001","article-title":"Bladder-sparing therapy for bacillus Calmette-Gu\u00e9rin\u2013unresponsive non\u2013muscle-invasive bladder cancer: International Bladder Cancer Group recommendations for optimal sequencing and patient selection","volume":"86","author":"Li","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.09.4137_b0060","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1001\/jama.2023.1792","article-title":"Cost-effectiveness thresholds used by study authors, 1990\u20132021","volume":"329","author":"Neumann","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2025.09.4137_b0065","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2025.09.4137_b0070","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s40273-018-0697-3","article-title":"Probabilistic sensitivity analysis in cost-effectiveness models: determining model convergence in cohort models","volume":"36","author":"Hatswell","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.eururo.2025.09.4137_b0075","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1097\/JU.0000000000001515","article-title":"Cost-effectiveness analysis of pembrolizumab for bacillus Calmette-Gu\u00e9rin-unresponsive carcinoma in situ of the bladder","volume":"205","author":"Wymer","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.09.4137_b0080","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.euo.2024.10.012","article-title":"Unmet need in non-muscle-invasive bladder cancer failing bacillus Calmette-Gu\u00e9rin therapy: a systematic review and cost-effectiveness analyses from the International Bladder Cancer Group","volume":"8","author":"D'Andrea","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.09.4137_b0085","doi-asserted-by":"crossref","unstructured":"NCCN. Clinical practice guidelines in oncology (NCCN guidelines): bladder cancer. 2024. https:\/\/doi.org\/10.6004\/jnccn.2024.0024.","DOI":"10.6004\/jnccn.2024.0024"},{"key":"10.1016\/j.eururo.2025.09.4137_b0090","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2025.09.4137_b0095","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/JU.0000000000004020","article-title":"Efficacy of intravesical nadofaragene firadenovec for patients with bacillus Calmette-Gu\u00e9rin-unresponsive nonmuscle-invasive bladder cancer: 5-year follow-up from a phase 3 trial","volume":"212","author":"Narayan","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.09.4137_b0100","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1002\/cncr.34502","article-title":"Comparative cost-effectiveness of neoadjuvant chemotherapy regimens for muscle-invasive bladder cancer: results according to VESPER data","volume":"128","author":"Joyce","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2025.09.4137_b0105","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/bju.14220","article-title":"Modelling cost-effectiveness of a biomarker-based approach to neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"122","author":"Lotan","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.09.4137_b0115","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1001\/jama.2022.7393","article-title":"Effect of robot-assisted radical cystectomy with intracorporeal urinary diversion vs open radical cystectomy on 90-day morbidity and mortality among patients with bladder cancer: a randomized clinical trial","volume":"327","author":"Catto","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2025.09.4137_b0120","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.eururo.2012.02.028","article-title":"Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients","volume":"61","author":"Hautmann","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.09.4137_b0125","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1097\/JU.0000000000001943","article-title":"Progression of disease after bacillus Calmette-Gu\u00e9rin therapy: refining patient selection for neoadjuvant chemotherapy before radical cystectomy","volume":"206","author":"Hensley","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.09.4137_b0130","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S1470-2045(23)00587-9","article-title":"Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study","volume":"25","author":"Pfister","year":"2024","journal-title":"Lancet Oncol"},{"issue":"16_suppl","key":"10.1016\/j.eururo.2025.09.4137_b0135","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1200\/JCO.2022.40.16_suppl.4508","article-title":"Final clinical results of pivotal trial of IL-15R\u03b1Fc superagonist N-803 with BCG in BCG-unresponsive CIS and papillary nonmuscle-invasive bladder cancer (NMIBC)","volume":"40","author":"Chamie","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.09.4137_b0140","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/JU.0000000000000688","article-title":"Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer","volume":"203","author":"Steinberg","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.09.4137_b0145","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.21037\/tcr-21-291","article-title":"Efficacy and toxicity in scheduled intravesical gemcitabine versus bacille Calmette-Gu\u00e9rin for Ta and T1 bladder cancer: a systematic review and meta-analysis","volume":"10","author":"Lu","year":"2021","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.eururo.2025.09.4137_b0150","article-title":"Intravesical gemcitabine for non-muscle invasive bladder cancer","volume":"6","author":"Han","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eururo.2025.09.4137_b0155","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine\u2013cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.09.4137_b0160","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.09.4137_b0165","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1371\/journal.pmed.0040284","article-title":"Optimal management of high-risk T1G3 bladder cancer: a decision analysis","volume":"4","author":"Kulkarni","year":"2007","journal-title":"PLoS Med"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825046755?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825046755?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T23:46:43Z","timestamp":1769816803000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283825046755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0302283825046755"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2025.09.4137","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness Analysis of Treatments for Bacillus Calmette-Gu\u00e9rin\u2013unresponsive Carcinoma in Situ of the Bladder","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2025.09.4137","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}